GCAC and ESG Consulting Firm to Offer Compliance & Sustainability to Leading US based Cannabis & Hemp brands
Vancouver, British Columbia, Canada, April 28, 2022 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, announce that Net Zero Analysis & Design (“NZA”) will be partnering to help clients of the new Efixii software platform called “clearESG” to create verifiable ESG (Environmental, Social and Governance) claims. clearESG, a new SaaS (Software-as-a-Service) offering will enable clients to evidence their ESG claims using the blockchain.
NZA, based in Chicago IL, will assist companies in the cannabis and hemp sectors with their facility audits for accurate greenhouse gas accounting, risk assessment, and the discovery of energy efficiency opportunities and new potential income streams. Facility audits aggregate data that will become crucial support for accurate corporate disclosures, compliance reporting, environmental, social, and governance (ESG) reporting, carbon-footprint reduction goals, climate-risk assessment, and discovery of carbon offset project opportunities. The partnership also offers third-party auditing for the U.N.-supported Principles for Responsible Investment (PRI), Global Reporting Initiative (GRI), Task Force on Climate-Related Financial Disclosures (TCFD), Climate Neutral Now initiative of the UNFCCC Secretariat, U.N.-supported Sustainable Development Goals (SDGs) and other widely-recognized reporting frameworks.
CEO Bradley Moore stated “Blockchain provides us with a technology platform that allows our company to quickly add transformational technologies and services. Developing tools that help the challenge of implementing sustainability goals not only helps our clients but makes an impact in the world. Working with a reputable company such as NZA, provides our soon to be released ESG product clients with the comfort and knowledge that not only can we assist with sustainability reporting but that we can also help with analysis that reduces costs and provides a potential new source of income for the grower and manufacturers”.
George Sullivan, Founder and CEO of Net Zero Analysis added, “Being able to work with GCAC’s blockchain technology to validate the sustainability claims for the cannabis and hemp industries will bring new positive exposure to the industry and the markets served. There is a big push for all supply chains to demonstrate carbon neutrality in line with U.N. definitions. The collaboration between NZA and GCAC will appropriately prepare companies to smoothly navigate the rapidly changing regulatory landscape and take advantage of new opportunities in the carbon marketplace. This, to our knowledge, will be a first for the cannabis and hemp sectors.”
Efixii is licensed to cultivators in a SaaS model and is a free-to-use app for cannabis consumers. All cannabis sold through the Portal generates a new sales-commission revenue stream for GCAC. Efixii’s cannabis data is the intellectual property (“IP”) of GCAC. This IP creates an inherent difficulty in replicating or competing with GCAC’s cannabis datasets. GCAC defined their protocols in a provisional U.S. patent application, ‘System of Process and Tracking Cannabis Products and Associated Method Using Blockchain’ filed with the USPTO on Dec. 17, 2020.
GCAC is a global leader in designing, developing, SaaS licensing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from SaaS licensing its technology and acquiring high-quality cannabis datasets that improve patient outcomes and become the world’s largest cannabis efficacy data provider.
This news release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.